Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation PlatformFinancing round led by Nextech Invest Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline NEW HAVEN, Conn., April 4, 2018-- Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the closing of a $55 million Series C financing. The financing was led by new investor Nextech Invest, with participation from additional new investors Deerfield Management, Hillhouse Capital, and Sirona Capital.